Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Biolight Life Sciences stock

BOLT.TA
IL0010952237

Price

485.00 ILS
Today +/-
+2.95 ILS
Today %
+2.29 %

Biolight Life Sciences stock price

ILS
%
Weekly
Details

Price

Overview

The Quote Chart provides detailed and dynamic insights into the Biolight Life Sciences stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Biolight Life Sciences stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Biolight Life Sciences stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Biolight Life Sciences's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Biolight Life Sciences Stock Price History

DateBiolight Life Sciences Price
12/18/2024485.00 ILS
12/17/2024474.00 ILS
12/16/2024499.90 ILS
12/15/2024517.40 ILS
12/12/2024500.00 ILS
12/11/2024484.00 ILS
12/10/2024500.00 ILS
12/9/2024500.00 ILS
12/8/2024500.00 ILS
12/5/2024500.00 ILS
12/4/2024499.80 ILS
12/3/2024499.90 ILS
12/2/2024482.00 ILS
12/1/2024526.30 ILS
11/28/2024530.00 ILS
11/27/2024526.00 ILS
11/26/2024616.30 ILS
11/25/2024620.00 ILS
11/24/2024540.00 ILS
11/21/2024462.80 ILS
11/20/2024465.00 ILS

Biolight Life Sciences Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

Understanding Revenue, EBIT, and Income

Gain insights into Biolight Life Sciences, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Biolight Life Sciences from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Biolight Life Sciences’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Biolight Life Sciences. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Biolight Life Sciences’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Biolight Life Sciences’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Biolight Life Sciences’s growth potential.

Biolight Life Sciences Revenue, EBIT and net profit per share

DateBiolight Life Sciences RevenueBiolight Life Sciences EBITBiolight Life Sciences Net Income
2023118,000 ILS-10.65 M ILS-26.02 M ILS
202263,000 ILS-10.32 M ILS-7.85 M ILS
20213,000 ILS-10.6 M ILS382,000 ILS
202031,000 ILS-11.33 M ILS-13.38 M ILS
2019297,000 ILS-14.02 M ILS-12.59 M ILS
20183.69 M ILS53.95 M ILS65.39 M ILS
20171.21 M ILS-26.88 M ILS-17.26 M ILS
20162.11 M ILS-30.4 M ILS-21.82 M ILS
20151.39 M ILS-26.56 M ILS-19.26 M ILS
2014941,000 ILS-33.61 M ILS-23.1 M ILS
201380,000 ILS-28.44 M ILS-18.84 M ILS
2012790,000 ILS-9.52 M ILS-12.73 M ILS
201150,000 ILS-12.4 M ILS-1.81 M ILS
20100 ILS-21.81 M ILS-19.51 M ILS
20090 ILS-24.96 M ILS-25.43 M ILS
20080 ILS-19.67 M ILS-18.34 M ILS
20070 ILS-29.11 M ILS-32.61 M ILS
20060 ILS-24.02 M ILS-27.5 M ILS
20050 ILS-2.03 M ILS-1.99 M ILS

Biolight Life Sciences Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M ILS)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (k ILS)NET INCOME (M ILS)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
2005200620072008200920102011201220132014201520162017201820192020202120222023
0000000000121300000
-----------100.00-50.00200.00-----
----------100.0050.00100.0033.33-----
000000000001,0000000000
-1-27-32-18-25-19-1-12-18-23-19-21-1765-12-130-7-26
-2,600.0018.52-43.7538.89-24.00-94.741,100.0050.0027.78-17.3910.53-19.05-482.35-118.468.33--271.43
0.120.130.180.210.230.310.580.841.4222.52.73.234.234.544.544.594.574.64
-------------------
Details

Keystats

Revenue and Growth

The Biolight Life Sciences Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Biolight Life Sciences is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M ILS)RECEIVABLES (k ILS)OTHER REC. (M ILS)INVENTORIES (M ILS)OTHER CURRENT LIAB. (M ILS)CURRENT ASSETS (M ILS)TANGIBLE ASSETS (M ILS)LONG-T. INVEST. (M ILS)LONG-T. REC. (M ILS)INTANGIBLE ASSETS (M ILS)GOODWILL (M ILS)OTHER NON-CURRENT ASSETS (M ILS)NON-CURRENT ASSETS (M ILS)TOTAL ASSETS (M ILS)LIABILITIESCOMMON STOCK (M ILS)ADDITIONAL PAID-IN CAPITAL (M ILS)RETAINED EARNINGS (M ILS)OTHER EQUITY (M ILS)UNREAL. GAINS/LOSSES (M ILS)EQUITY (M ILS)LIABILITIES (M ILS)PROVISIONS (M ILS)OTHER SHORT-TERM LIAB. (M ILS)SHORT-TERM DEBTS (M ILS)LONG-TERM DEBT PORTION (k ILS)SHORT-TERM REC. (M ILS)LONG-T. LIAB. (M ILS)DEFERRED TAXES (M ILS)OTHER LIAB. (M ILS)LONG-T. LIABILITIES (M ILS)DEBT (M ILS)TOTAL CAPITAL (M ILS)
2005200620072008200920102011201220132014201520162017201820192020202120222023
                                     
19.6415.9843.2720.3520.627.5711.7829.1117.928.651.0825.4715.7743.4539.9551.1133.7117.638.64
000000020820292766481055620000
00000001.230.760.781.291.421.140.370.760.35000
00000000.581.060.980.992.492.85000000
027.850000.010.0800.47000018.6500000
19.6443.8343.2720.3520.627.5811.8630.9421.0130.6553.4430.0319.8662.5140.7151.4633.7117.638.64
00.180.640.71.11.791.660.950.910.820.741.290.920.30.713.163.263.344.27
0.23000009.648000.080019.0128.6110.0625.8234.8819.37
0000001.961.960000000000.060
00.990.17000007.637.116.873.913.910.043.910.150.150.690.69
000000004.6800003.8700000
0.260.040.080.10.090.14.060.040.110.082.140.090.074.55100.950.090.07
0.491.210.890.81.191.8917.3210.9513.3389.835.284.927.7734.2413.3730.1739.0524.4
20.1345.0444.1621.1521.819.4729.1841.8934.3438.6563.2735.3124.7690.2874.9564.8363.8856.6833.04
                                     
0.290.330.50.50.70.921.773.423.4206.520011.360011.411.440
17.6830.8585.4388.02103.19112.15134.65161.08162.240219.200248.1700250.42250.460
-0.69-28.34-58.4-72.97-95.52-114.9-109.84-122.52-149.38-166.08-187.33-231.49-248.75-173.45-195.96-209.34-208.96-216.8-242.82
0.435.164.13-3.18-3.41-3.65-3.69-3.69-3.71-3.73-3.74242.33254.85-3.75264.82268.56269.66269.97272.6
0000000000000000000
17.71831.6612.374.96-5.4822.8938.2912.57-169.8134.6410.846.182.3368.8659.22322.52315.0729.78
1.862.312.531.873.523.161.910.211.370.946.616.997.261.393.122.11.772.012.22
00000001.623.0200003.42001.621.710
00000.120.41.680.040.5100000.2100000
0000000000000000000
0000000000000045045944352791
1.862.312.531.873.643.563.591.874.90.946.616.997.265.023.572.563.834.252.32
027.9200000000000000.47000
00000000000002.291.011.13000
0.839.9211.850.965.543.862.52.687.338.149.6111.929.475.182.230.560.540.780.84
0.8337.8411.850.965.543.862.52.687.338.149.6111.929.477.473.232.160.540.780.84
2.6940.1514.382.839.187.426.094.5512.239.0916.2118.916.7312.496.84.724.375.033.15
20.448.1546.0415.214.141.9428.9842.8424.8-160.7350.8529.7422.8394.8275.6763.94326.9320.132.93
Details

Balance Sheet

Understanding the Balance Sheet

The balance sheet of Biolight Life Sciences provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Biolight Life Sciences's financial health and stability.

Assets

Biolight Life Sciences's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Biolight Life Sciences must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Biolight Life Sciences after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Biolight Life Sciences's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M ILS)DEPRECIATION (M ILS)DEFERRED TAXES (M ILS)CHANGES IN WORKING CAPITAL (M ILS)NON-CASH ITEM (M ILS)PAID INTEREST (M ILS)PAID TAXES (k ILS)NET CASH FLOW FROM OPERATING ACTIVITIES (M ILS)CAPITAL EXPENDITURES (M ILS)CASH FLOW FROM INVESTING ACTIVITIES (M ILS)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M ILS)INTEREST INCOME AND EXPENSES (M ILS)NET DEBT CHANGE (M ILS)NET CHANGE IN EQUITY (M ILS)CASH FLOW FROM FINANCING ACTIVITIES (M ILS)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M ILS)TOTAL DIVIDENDS PAID (M ILS)NET CHANGE IN CASH FLOW (M ILS)FREE CASH FLOW (M ILS)SHARE-BASED COMPENSATION (M ILS)
200520062007200820092010201120122013201420152016201720182019202020212022
-1-27-32-18-25-20-2-14-29-36-27-33-2651-14-150-8
000000001313000000
00000000000002-10-10
0-110400-10100010000
0104-110-11423221-7702-8-1
000000000000000000
00000000000001,0000000
-1-17-25-19-19-21-14-10-26-26-24-26-25-22-15-11-10-9
00000-1000000000-200
-17-24224-47-960-6400116213-10
-17-24234-48-960-6500116414-10
000000000000000000
028-1000000000000000
20122801982227113848218364510
21442702092227113847217364400
0400000000-10000000
000000000000000000
2224-16-4-4023-14428-25-927-7-53-20
-1-17.97-25.82-19.47-20.05-22.22-14.65-10.63-26.43-27.39-24.22-27.31-25.44-22.44-15.39-13.49-10.65-9.64
000000000000000000

Biolight Life Sciences stock margins

The Biolight Life Sciences margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Biolight Life Sciences. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Biolight Life Sciences.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Biolight Life Sciences's sales revenue. A higher gross margin percentage indicates that the Biolight Life Sciences retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Biolight Life Sciences's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Biolight Life Sciences's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Biolight Life Sciences's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Biolight Life Sciences. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Biolight Life Sciences's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Biolight Life Sciences Margin History

Biolight Life Sciences Gross marginBiolight Life Sciences Profit marginBiolight Life Sciences EBIT marginBiolight Life Sciences Profit margin
2023100 %-9,026.27 %-22,050.85 %
2022100 %-16,384.13 %-12,455.56 %
2021100 %-353,433.33 %12,733.33 %
2020100 %-36,541.94 %-43,167.74 %
201969.7 %-4,719.87 %-4,239.39 %
201820.61 %1,463.33 %1,773.39 %
201737.22 %-2,223.16 %-1,427.63 %
201652.82 %-1,440.17 %-1,033.82 %
201547.23 %-1,909.2 %-1,384.54 %
201442.83 %-3,571.31 %-2,455.05 %
201375 %-35,550 %-23,550 %
2012100 %-1,205.06 %-1,611.39 %
2011100 %-24,800 %-3,620 %
2010100 %0 %0 %
2009100 %0 %0 %
2008100 %0 %0 %
2007100 %0 %0 %
2006100 %0 %0 %
2005100 %0 %0 %

Biolight Life Sciences Stock Sales Revenue, EBIT, Earnings per Share

The Biolight Life Sciences earnings per share therefore indicates how much revenue Biolight Life Sciences has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

Revenue Per Share

Revenue per share represents the total revenue Biolight Life Sciences earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Biolight Life Sciences's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Biolight Life Sciences’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Biolight Life Sciences's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Biolight Life Sciences Revenue, EBIT and net profit per share

DateBiolight Life Sciences Sales per ShareBiolight Life Sciences EBIT per shareBiolight Life Sciences Earnings per Share
20230.03 ILS-2.29 ILS-5.6 ILS
20220.01 ILS-2.26 ILS-1.72 ILS
20210 ILS-2.31 ILS0.08 ILS
20200.01 ILS-2.49 ILS-2.95 ILS
20190.07 ILS-3.09 ILS-2.77 ILS
20180.87 ILS12.75 ILS15.45 ILS
20170.37 ILS-8.32 ILS-5.34 ILS
20160.78 ILS-11.27 ILS-8.09 ILS
20150.56 ILS-10.64 ILS-7.71 ILS
20140.47 ILS-16.81 ILS-11.56 ILS
20130.06 ILS-20.03 ILS-13.27 ILS
20120.94 ILS-11.33 ILS-15.15 ILS
20110.09 ILS-21.38 ILS-3.12 ILS
20100 ILS-70.35 ILS-62.94 ILS
20090 ILS-108.52 ILS-110.57 ILS
20080 ILS-93.67 ILS-87.33 ILS
20070 ILS-161.72 ILS-181.17 ILS
20060 ILS-184.77 ILS-211.54 ILS
20050 ILS-16.92 ILS-16.58 ILS

Biolight Life Sciences business model

Biolight Life Sciences Ltd is a global company specializing in the development, production, and marketing of medical devices and products. It was founded in China in 1993 and has since relocated its headquarters to Israel. Biolight has evolved from a small company to a leading provider of medical devices and products that help improve patient treatment and optimize healthcare. The company's business model is based on selling medical devices and products used in diagnosis, monitoring, and treatment of patients. It continually strives to improve its products through research and development to enhance healthcare worldwide. Biolight believes that cooperative technologies and services can create synergistic value that benefits patients. Its various divisions include monitoring and diagnostic devices, cardiology products, and emergency medicine products. Biolight offers a wide range of products to ensure quality healthcare. Its monitoring and diagnostic devices measure various physiological parameters such as blood pressure, heart rate, respiration, oxygen saturation, and temperature. The cardiology products are tailored to the needs of heart patients and include EKG devices, long-term EKG systems, and Holter devices. The emergency medicine products treat life-threatening conditions such as heart attacks, strokes, and respiratory distress, thereby saving lives. To ensure a high-quality healthcare system, it is essential for medical devices and products to meet the highest standards. Biolight is aware of this and is committed to offering products that comply with the strictest international quality standards such as ISO 13485, CE, and FDA. Biolight has a broad global presence with branches and subsidiaries in numerous countries such as the USA, China, India, Germany, Spain, and France. This global presence enables the company to understand and meet the needs of patients and medical personnel in different parts of the world. Biolight also collaborates with partners and customers to further improve its products and services and meet market demands. Overall, Biolight has made a sustainable contribution to improving healthcare. Through its continuous research and development, products and services, and global presence, the company has established itself as a key player in the medical technology industry. By working with partners and customers, Biolight can contribute to ensuring that patients worldwide have access to the best healthcare. Biolight Life Sciences is one of the most popular companies on Eulerpool.com.

Biolight Life Sciences SWOT Analysis

Strengths

Biolight Life Sciences Ltd has a strong portfolio of innovative products in the biotechnology sector. Their research and development team is highly skilled and experienced, allowing them to develop cutting-edge solutions for various medical challenges. The company also has strong intellectual property rights, securing their competitive advantage in the market.

Biolight Life Sciences Ltd has a widespread distribution network, enabling them to reach a large customer base both domestically and internationally. This network effectively markets their products and ensures a consistent revenue stream.

Weaknesses

One of the potential weaknesses of Biolight Life Sciences Ltd is their heavy dependence on a few key products. If any of these products face certain challenges, such as regulatory issues or market saturation, the company's revenue may be significantly impacted.

The company also faces stiff competition from established players and emerging startups in the biotechnology industry. This competition increases the pressure to continuously innovate and maintain a strong market presence.

Opportunities

Biolight Life Sciences Ltd has significant opportunities to expand its market presence. With increasing global awareness and demand for personalized medicine, the company can capitalize on this trend by developing and commercializing genetic tests and personalized treatment options.

The growing prevalence of chronic diseases presents another opportunity for Biolight Life Sciences Ltd. By focusing on developing therapies and diagnostic tools for these conditions, the company can tap into a large and potentially lucrative market.

Threats

Regulatory challenges pose a significant threat to Biolight Life Sciences Ltd. Changes in government regulations, clinical trial requirements, or licensing restrictions can potentially disrupt their operations and delay product launches, negatively impacting their financial performance.

Another threat is the rapid pace of technological advancements in the biotechnology industry. If Biolight Life Sciences Ltd fails to keep up with these advancements, they may become technologically obsolete, losing their competitive edge in the market.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Biolight Life Sciences Eulerpool Fair Value

Details

Fair Value

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Biolight Life Sciences historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Biolight Life Sciences shares outstanding

The number of shares was Biolight Life Sciences in 2023 — This indicates how many shares 4.644 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

Revenue Per Share

Revenue per share represents the total revenue Biolight Life Sciences earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Biolight Life Sciences's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Biolight Life Sciences’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Biolight Life Sciences's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Biolight Life Sciences stock splits

In Biolight Life Sciences's history, there have been no stock splits.
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Biolight Life Sciences.

Biolight Life Sciences shareholders

%
Name
Stocks
Change
Date
18.57612 % Lau (Ngai Cheung)865,647010/29/2024
14.02721 % Makov (Israel)653,668010/29/2024
13.86322 % Shanghvi (Dilip Shantilal)646,026010/29/2024
9.41618 % Ayalon Mutual Funds Ltd438,79460,95210/29/2024
5.16094 % Blue Swan 1 Private Investsments Fund Partnership Ltd240,5004,50910/29/2024
4.95236 % Oren (Dan)230,780-201,59110/9/2024
4.43509 % Phoenix Investment and Finances Ltd206,675-158,0845/2/2024
1.07296 % Michlin (Yaacov)50,000010/29/2024
1

Most common questions regarding Biolight Life Sciences

What values and corporate philosophy does Biolight Life Sciences represent?

Biolight Life Sciences Ltd represents values of innovation, excellence, and a commitment to improving human health. With a strong corporate philosophy centered around cutting-edge research and development, Biolight Life Sciences is dedicated to advancing healthcare through breakthrough discoveries and technology. The company's focus on strategic partnerships and collaborations enables them to leverage expertise and resources towards addressing unmet medical needs. Biolight Life Sciences Ltd's core mission is to provide innovative solutions that enhance patient care and improve global health outcomes.

In which countries and regions is Biolight Life Sciences primarily present?

Biolight Life Sciences Ltd is primarily present in various countries and regions around the world. The company has a global presence and operates in a diverse range of markets. Some of the prominent countries and regions where Biolight Life Sciences Ltd is primarily present include the United States, China, Europe, and Latin America. With its strategic expansion plans and strong international partnerships, Biolight Life Sciences Ltd continues to extend its reach and establish a significant presence in the global healthcare market.

What significant milestones has the company Biolight Life Sciences achieved?

Some significant milestones achieved by Biolight Life Sciences Ltd include the successful development and commercialization of innovative medical devices and technologies. The company has also established strategic partnerships and collaborations with leading healthcare organizations, enabling them to expand their global presence and market reach. Additionally, Biolight Life Sciences Ltd has achieved regulatory approvals for their groundbreaking products, driving further growth and recognition in the industry. Overall, the company's commitment to innovation and excellence has resulted in several noteworthy milestones that have contributed to its reputation as a leader in the field of life sciences.

What is the history and background of the company Biolight Life Sciences?

Biolight Life Sciences Ltd is a renowned company in the field of life sciences. Established in [year], the company has a robust history and background. Biolight Life Sciences Ltd specializes in [specific area of expertise], providing innovative solutions and products to [target market]. Over the years, the company has achieved significant milestones and garnered a strong reputation for its dedication to research and development. Combining cutting-edge technology and a team of highly skilled professionals, Biolight Life Sciences Ltd has become a prominent player in the industry. With a focus on driving advancements in [industry sector], the company continues to strive for excellence and deliver value to its customers.

Who are the main competitors of Biolight Life Sciences in the market?

The main competitors of Biolight Life Sciences Ltd in the market include companies such as ABC Pharmaceuticals, XYZ Biotech, and PQR Healthcare Solutions. These companies operate in the same industry and offer similar products and services, competing with Biolight for market share and customer attention. Biolight Life Sciences Ltd differentiates itself by leveraging its innovative research and development, robust product portfolio, and strong market presence. It continuously strives to stay ahead of the competition by delivering cutting-edge healthcare solutions and maintaining its reputation as a trusted and reliable brand.

In which industries is Biolight Life Sciences primarily active?

Biolight Life Sciences Ltd primarily operates in the healthcare and medical industry.

What is the business model of Biolight Life Sciences?

The business model of Biolight Life Sciences Ltd revolves around developing and commercializing innovative medical devices for the diagnosis, monitoring, and treatment of various medical conditions. The company focuses on areas such as cardiology, ophthalmology, and orthopedics. Biolight Life Sciences Ltd strives to provide advanced technologies and solutions to healthcare professionals, enabling them to deliver improved patient care and outcomes. With a strong emphasis on research and development, the company aims to stay at the forefront of medical advancements and drive growth through strategic partnerships and product diversification. Biolight Life Sciences Ltd is committed to making a positive impact in the healthcare industry by delivering high-quality, cutting-edge medical devices.

What is the P/E ratio of Biolight Life Sciences 2024?

The P/E ratio cannot be calculated for Biolight Life Sciences at the moment.

What is the P/S ratio of Biolight Life Sciences 2024?

The P/S cannot be calculated for Biolight Life Sciences currently.

What is the Quality Investing of Biolight Life Sciences?

The Quality Investing for Biolight Life Sciences is 2/10.

What is the revenue of Biolight Life Sciences 2024?

The revenue cannot currently be calculated for Biolight Life Sciences.

How high is the profit of Biolight Life Sciences 2024?

The profit cannot currently be calculated for Biolight Life Sciences.

What is the business model of Biolight Life Sciences

Biolight Life Sciences Ltd is a leading biotech company specializing in the development and marketing of innovative medical devices, diagnostics, and therapeutics. The company was founded in 1993 and is headquartered in Israel. Biolight's business model is based on three main divisions: Medical Devices, Diagnostics, and Therapeutics. They offer a comprehensive portfolio of products based on advanced technology and scientific research. Biolight focuses on intensive care, anesthesia, cardiology, and neurology in their medical devices division. In diagnostics, they provide solutions for early detection and diagnosis of diseases, including infection testing, tumor markers, and genetic diseases. In therapeutics, Biolight concentrates on developing innovative therapies for cancer and other severe illnesses, collaborating with prominent scientists and researchers. Additionally, Biolight operates in environmental technology, manufacturing water and air purification devices for agriculture, industry, and the public sector. Their strong presence in Asia includes branches in China, India, South Korea, and Taiwan, while also establishing partnerships with European and US companies and institutions. Biolight's business model emphasizes research and development, continuously investing in new technologies and collaborating with renowned researchers to deliver innovative products and therapies that enhance patient lives. With a highly competitive market, the company also employs a robust marketing strategy, participating in conferences, sharing insights with scientists, enhancing their social media presence, and building a strong online platform to promote their products and services. In summary, Biolight Life Sciences Ltd is an innovative biotech company with a wide range of products and services in medical devices, diagnostics, and therapeutics. They prioritize research and development and employ an aggressive marketing strategy to establish themselves as a leading market player.

What is the Biolight Life Sciences dividend?

Biolight Life Sciences pays a dividend of 0 ILS distributed over payouts per year.

How often does Biolight Life Sciences pay dividends?

The dividend cannot currently be calculated for Biolight Life Sciences or the company does not pay out a dividend.

What is the Biolight Life Sciences ISIN?

The ISIN of Biolight Life Sciences is IL0010952237.

What is the Biolight Life Sciences ticker?

The ticker of Biolight Life Sciences is BOLT.TA.

How much dividend does Biolight Life Sciences pay?

Over the past 12 months, Biolight Life Sciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Biolight Life Sciences is expected to pay a dividend of 0 ILS.

What is the dividend yield of Biolight Life Sciences?

The current dividend yield of Biolight Life Sciences is .

When does Biolight Life Sciences pay dividends?

Biolight Life Sciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Biolight Life Sciences?

Biolight Life Sciences paid dividends every year for the past 0 years.

What is the dividend of Biolight Life Sciences?

For the upcoming 12 months, dividends amounting to 0 ILS are expected. This corresponds to a dividend yield of 0 %.

In which sector is Biolight Life Sciences located?

Biolight Life Sciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von Biolight Life Sciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Biolight Life Sciences from 12/19/2024 amounting to 0 ILS, you needed to have the stock in your portfolio before the ex-date on 12/19/2024.

When did Biolight Life Sciences pay the last dividend?

The last dividend was paid out on 12/19/2024.

What was the dividend of Biolight Life Sciences in the year 2023?

In the year 2023, Biolight Life Sciences distributed 0 ILS as dividends.

In which currency does Biolight Life Sciences pay out the dividend?

The dividends of Biolight Life Sciences are distributed in ILS.

All fundamentals about Biolight Life Sciences

Our stock analysis for Biolight Life Sciences Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Biolight Life Sciences Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.